

Original article

Diabetes mellitus in patients with heart failure and effect modification of risk factors for short-term mortality: An observational study from the *Registro Colombiano de Falla Cardíaca (RECOLFACA)*

Luis Eduardo Echeverría¹, Clara Saldarriaga², Sebastián Campbell-Quintero³, Lisbeth Natalia Morales-Rodríguez⁴, Juan David López-Ponce de León⁵, Andrés Felipe Buitrago⁶, Erika Martínez-Carreño⁷, Jorge Alberto Sandoval-Luna⁸, Alexis Llamas⁹, Gustavo Adolfo Moreno-Silgado¹⁰, Julián Vanegas-Eljach¹¹, Nelson Eduardo Murillo-Benítez¹², Ricardo Gómez-Paláu¹³, Alex Arnulfo Rivera-Toquica¹⁴, Juan Esteban Gómez-Mesa^{5,15}, RECOLFACA research group*

¹ Departamento de Cardiología, Fundación Cardiovascular de Colombia, Bucaramanga, Colombia

² Departamento de Cardiología, Clínica Cardio VID, Medellín, Colombia

³ Departamento de Cardiología, Clínica Medilaser, Florencia, Colombia

⁴ Departamento de Cardiología, Clínica Medilaser, Neiva, Colombia

⁵ Departamento de Cardiología, Fundación Valle de Lili, Cali, Colombia

⁶ Departamento de Cardiología, Fundación Santa Fe de Bogotá, Bogotá, D.C., Colombia

⁷ Departamento de Cardiología, Institución Clínica Iberoamérica Sanitas, Barranquilla, Colombia

⁸ Departamento de Cardiología, Cardiología Siglo XXI, Ibagué, Colombia

⁹ Departamento de Cardiología, Clínica Las Américas, Medellín, Colombia

¹⁰ Departamento de Cardiología, Hospicardio, Montería, Colombia

¹¹ Departamento de Cardiología, Hospital Alma Máter, Antioquia, Colombia

¹² Departamento de Cardiología, Angiografía de Occidente, Cali, Colombia

¹³ Departamento de Cardiología, Clínica Imbanaco-Grupo Quirón Salud, Cali, Colombia

¹⁴ Departamento de Cardiología, Centro Médico para el Corazón, Pereira, Colombia

¹⁵ Departamento de Ciencias de la Salud, Universidad Icesi, Cali, Colombia

* The list of all investigators from the RECOLFACA group is presented at the end of this manuscript in the acknowledgments section

Received: 18/04/2023

Accepted: 14/05/2024

Published: 15/05/2024

Citation:

Echeverría LE, Saldarriaga C, Campbell-Quintero S, Morales-Rodríguez LN, López-Ponce de León JD, Buitrago AF, *et al.* Diabetes mellitus in patients with heart failure and effect modification of risk factors for short-term mortality: An observational study from the *Registro Colombiano de Falla Cardíaca (RECOLFACA)*. *Biomédica*. 2024;44(Supl.1):182-97. <https://doi.org/10.7705/biomedica.6951>

Corresponding author:

Juan Esteban Gómez-Mesa, Departamento de Cardiología, Fundación Valle de Lili, Calle 98 N°18-49, Cali, Colombia
Phone number: +57 (602) 331 9090, extension 7453 and 7422
juan.gomez.me@fvli.org.co

Author's contributions:

Luis Eduardo Echeverría, Juan Esteban Gómez-Mesa, Clara Saldarriaga and Alex Arnulfo Rivera-Toquica: conceptualization, formal analysis, funding acquisition, investigation, methodology, project administration, resources, and visualization. Juan Esteban Gómez-Mesa contributed to data curation, software management, supervision, and validation. All authors made substantial contributions to the conception or design of the work, the acquisition, analysis, and interpretation of data.

Funding:

No funding bodies had any role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Conflicts of interest:

The authors declare that they have no conflict of interest.

Introduction. Heart failure and type 2 diabetes mellitus are critical public health issues. **Objective.** To characterize the risk factors for mortality in patients with heart failure and type 2 diabetes mellitus from a large registry in Colombia and to evaluate the potential effect modifications by type 2 diabetes mellitus over other risk factors.

Materials and methods. Heart failure patients with and without type 2 diabetes mellitus enrolled in the *Registro Colombiano de Falla Cardíaca (RECOLFACA)* were included. RECOLFACA enrolled adult patients with heart failure diagnosis from 60 medical centers in Colombia during 2017-2019. The primary outcome was all-cause mortality. Survival analysis was performed using adjusted Cox proportional hazard models.

Results. A total of 2514 patients were included, and the prevalence of type 2 diabetes mellitus was 24.7% (n = 620). We found seven independent predictors of short-term mortality for the general cohort, chronic obstructive pulmonary disease, sinus rhythm, triple therapy, nitrates use, statins use, anemia, and hyperkalemia. In the type 2 diabetes mellitus group, only the left ventricle diastolic diameter was an independent mortality predictor (HR = 0.96; 95% CI: 0.93-0.98). There was no evidence of effect modification by type 2 diabetes mellitus on the relationship between any independent predictors and all-cause mortality. However, a significant effect modification by type 2 diabetes mellitus between smoking and mortality was observed.

Conclusions. Patients with type 2 diabetes mellitus had higher mortality risk. Our results also suggest that type 2 diabetes mellitus diagnosis does not modify the effect of the independent risk factors for mortality in heart failure evaluated. However, type 2 diabetes mellitus significantly modify the risk relation between mortality and smoking in patients with heart failure.

Keywords: Diabetes mellitus; diabetes mellitus, type 2; heart failure; risk factors; mortality; Latin America; Colombia.

Diabetes mellitus en pacientes con insuficiencia cardíaca y modificación del efecto de los factores de riesgo de mortalidad a corto plazo: un estudio observacional del Registro Colombiano de Falla Cardíaca (RECOLFACA)

Introducción. La insuficiencia cardíaca y la diabetes mellitus de tipo 2 son problemas críticos de salud pública.

Objetivo. Caracterizar los factores de riesgo de mortalidad en pacientes con insuficiencia cardíaca y la diabetes mellitus de tipo 2 de un registro grande en Colombia y evaluar las posibles modificaciones del efecto de la diabetes mellitus de tipo 2 sobre otros factores de riesgo.

Materiales y métodos. Se incluyeron pacientes con insuficiencia cardíaca con y sin diabetes mellitus de tipo 2, inscritos en el Registro Colombiano de Insuficiencia Cardíaca (RECOLFACA). RECOLFACA incorporó pacientes adultos con diagnóstico de insuficiencia cardíaca de 60 centros médicos de Colombia durante 2017-2019. El resultado primario fue la mortalidad por todas las causas. El análisis de supervivencia se realizó utilizando modelos ajustados de riesgos proporcionales de Cox.

Resultados. Se incluyeron 2.514 pacientes, la prevalencia de diabetes mellitus de tipo 2 fue del 24,7 % (n = 620). Encontramos siete predictores independientes de mortalidad a corto plazo para la enfermedad pulmonar obstructiva crónica del grupo sin diabetes mellitus de tipo 2, el ritmo sinusal, la terapia triple, el uso de nitratos, el uso de estatínicos, la anemia y la hiperpotasemia. En el grupo de diabetes mellitus de tipo 2, solo el diámetro diastólico del ventrículo izquierdo fue un predictor de mortalidad independiente (HR = 0,96; IC_{95%}: 0,93 - 0,98). No hubo evidencia de modificación del efecto de la diabetes mellitus de tipo 2 sobre la relación entre ningún predictor independiente y la mortalidad por todas las causas. Sin embargo, se observó una modificación significativa del efecto de la diabetes mellitus de tipo 2 entre el tabaquismo y la mortalidad.

Conclusiones. Los pacientes con diabetes mellitus de tipo 2 tuvieron mayor riesgo de mortalidad. Los resultados también sugieren que el diagnóstico de diabetes mellitus de tipo 2 no modifica el efecto de los factores de riesgo independientes de mortalidad en IC evaluados. Sin embargo, la diabetes mellitus de tipo 2 modifica significativamente la relación de riesgo entre mortalidad y tabaquismo en pacientes con insuficiencia cardíaca, posiblemente debido a un efecto sinérgico negativo que resulta en lesión vascular.

Palabras clave: diabetes mellitus; diabetes mellitus de tipo 2; insuficiencia cardíaca; factores de riesgo; mortalidad; América Latina; Colombia.

Heart failure and type 2 diabetes mellitus represent two of the most relevant non-transmissible chronic diseases worldwide, representing a critical public health issue nowadays (1). An estimated 6.2 million individuals were living with heart failure in the United States between 2013 and 2016, while its prevalence in Latin American countries was 1% [95% confidence interval (95%CI): 0.1%-2.7%] between 1994 and 2014 (2,3). Moreover, approximately 26 million people are affected by heart failure worldwide, representing an estimated health expenditure of around USD \$31 billion by 2012, which is expected to increase by 127% by 2030 (3). On the other hand, an estimated 462 million individuals have been diagnosed with type 2 diabetes mellitus by 2017, reflecting a prevalence rate of 6059 cases per 100,000 population. Moreover, around one million deaths per year can be attributed to diabetes alone, positioning this disease as the ninth leading cause of mortality worldwide (4).

Heart failure and type 2 diabetes mellitus commonly coexist, exponentially increasing the risk of complications in the patients affected by both conditions (5). This coexistence is derived from the common pathophysiological pathways both heart failure and type 2 diabetes mellitus share (1,6). This association was first observed in the Framingham study after more than 40 years of follow-up. In this cohort, men and women with diabetes mellitus had a two- and five-times higher risk of developing heart failure compared to the general population, respectively (7). These findings could partially explain why the prevalence of type 2 diabetes mellitus in heart failure patients is exceptionally high (estimated to be around 30% to 50%) (5). However, a new hypothesis suggesting a bidirectional relation between heart failure and type 2 diabetes mellitus has also been gaining relevance in recent years, giving further explanation to this observed prevalence, and highlighting the importance of type 2 diabetes mellitus and heart failure coexistence (1).

In this context, type 2 diabetes mellitus can modify heart failure's disease course, increasing the risk of adverse outcomes, including rehospitalizations, prolonged hospital stays, and even mortality, mainly in the context of heart failure with reduced ejection fraction (8,9). Nonetheless, the knowledge of the potential interactions and effect modifications that type 2 diabetes mellitus can elicit on mortality-associated risk factors is still poorly understood (10). Understanding these is crucial for an optimal approach and adequate guiding of the patient's management to achieve the expected goals (11). The present study aimed to characterize the risk factors for mortality in patients with heart failure and type 2 diabetes mellitus from RECOLFACA and evaluate the potential effect modifications by type 2 diabetes mellitus over other risk factors.

Materials and methods

Study design and population

The RECOLFACA is a prospective cohort study conducted at 60 medical centers, heart failure clinics, and cardiology outpatient centers in Colombia. Patient enrollment started in February 2017 and ended in October 2019. It included all adult patients (older than 18 years) with a clinical diagnosis of heart failure of any etiology based on the guideline recommendations at the time of inclusion, with at least one hospitalization due to heart failure in the 12 months before enrollment. Specific inclusion and exclusion criteria, along with additional methodologic characteristics of the registry, are described elsewhere (12,13).

Data collection

Information regarding sociodemographic, clinical, and laboratory variables was registered at baseline. Type 2 diabetes mellitus diagnosis was based on self-report, laboratory test results (fasting glucose level > 125 mg/dl or glycated hemoglobin [HbA1c] of more than 7%), or glucose-lowering therapy use. Heart failure severity was assessed using the New York Heart Association (NYHA) classification.

An ischemic disease diagnosis was registered if the patient underwent a coronary revascularization procedure or if a previous myocardial infarction history was present. The following comorbidities were assessed: chronic kidney disease, arterial hypertension, atrial fibrillation, chronic obstructive pulmonary disease (COPD), thyroid disease, and dyslipidemia. The estimated glomerular filtration rate (eGFR) was calculated with the MDRD formula, and an eGFR < 60 ml/min/1.73 m² was considered the cut-off for chronic kidney disease. Available data on additional echocardiographic variables was registered. The left ventricle ejection fraction variable was available from 2041 patients (81.2%), 502 from the type 2 diabetes mellitus group (80.9%) and 1539 from the non-type 2 diabetes mellitus group (81.3%), the systolic diameter of the left ventricle variable was available from 1305 patients (51.9%), 299 from the type 2 diabetes mellitus group (48.2%) and 1006 from the non-type 2 diabetes mellitus group (53.1%), and the valvular pathology variable was available from all patients. We considered triple therapy as the presence of the prescription of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), plus a beta-blocker and a mineralocorticoid receptor antagonist.

Outcomes

The primary outcome of the study was all-cause mortality. Data on this outcome was collected using a questionnaire applied by each heart failure clinic and center two times per year. The current results represent the data from the follow-up performed after six months of enrollment into the registry. Each center also reviewed each patient's clinical records to assess specific data about the outcomes.

Statistical analysis

At first, the total sample was divided into two groups (diabetics vs. non-diabetics). Baseline characteristics were described as medians and quartiles for quantitative variables, or absolute counts, proportions and percentages for categorical variables. Differences between groups were assessed using Pearson's chi square and Fisher's exact tests for categorical variables and Mann-Whitney U tests for quantitative variables. The cumulative incidence of the mortality events was calculated with their respective 95% confidence intervals. Survival analysis was performed using the Kaplan-Meier method and adjusted Cox proportional hazard models.

A multivariable Cox regression model including all the variables significantly associated with mortality was generated; after this, variables independently associated with this outcome were selected. The final model included all the independent predictors of mortality and was also adjusted by age, sex, chronic kidney disease diagnosis, NYHA classification, and left ventricle ejection fraction. Effect modification was assessed using multiple Cox regression and the Mantel-Haenszel method.

In summary, an effect modifier corresponds to a variable that differentially modifies a risk factor's observed effect regarding a determined outcome. This results in different risk estimates between the evaluated groups when the effect modifier is present. A p value less than 0.05 (two-tailed test) was considered as statistically significant. All analyses were performed using statistical package Stata™, version 15 (Station College, Texas USA).

Results

From the total 2528 patients included in RECOLFACA between February 2017 and October 2019, 2514 patients had information regarding type 2 diabetes mellitus diagnosis. The prevalence of type 2 diabetes mellitus among these patients was 24.6% (n = 620).

Baseline characteristics

No significant demographic differences were observed between the groups regarding sex, age, and ethnicity (table 1). However, patients with type 2 diabetes mellitus diagnosis had a significantly higher prevalence of hypertension, coronary disease, valvular disease, chronic kidney disease, and dyslipidemia. On the other hand, non-diabetic individuals had more frequently a diagnosis of atrial fibrillation, valvular disease, and Chagas' disease (table 1). Regarding the pharmacological therapy, patients with type 2 diabetes mellitus diagnosis were more frequently prescribed angiotensin receptor blockers, antiplatelets, and statins, while non-diabetics reported higher use of MRA, ACEI, and digoxin. Finally, diabetic patients showed a lower value of hemoglobin, and glomerular filtration rate while having a higher prevalence of electrolytic disorders.

Table 1. Sociodemographic and clinical characteristics of patients with heart failure diagnosis enrolled in the *Registro Colombiano de Insuficiencia Cardíaca (RECOLFACA)* by type 2 diabetes mellitus diagnosis

	Type 2 diabetes mellitus (N = 2514)			p value
	No (n = 1894) n (%)	Yes (n = 620) n (%)	Total n (%)	
Sex				0.195
Female	790 (41.7)	277 (44.7)	1067 (42.4)	
Male	1104 (58.3)	343 (55.3)	1447 (57.6)	
Age (years)	69 (59.78)	69 (62.77)	69 (59.78)	0.443
Race				0.400
Asian	0 (0.0)	1 (0.2)	1 (0.0)	
White	85 (4.5)	31 (5.0)	116 (4.6)	
Indigenous	9 (0.5)	1 (0.2)	10 (0.4)	
Hispanic	1398 (73.8)	455 (73.4)	1853 (73.7)	
Mestizo	342 (18.1)	116 (18.7)	458 (18.2)	
African-American	60 (3.2)	16 (2.6)	76 (3.0)	
Hypertension	1283 (67.7)	528 (85.2)	1811 (72.0)	< 0.001
Alcoholism	69 (3.6)	17 (2.7)	86 (3.4)	0.284
Cancer	75 (4.0)	26 (4.2)	101 (4.0)	0.797
Depression	34 (1.8)	13 (2.1)	47 (1.9)	0.630
Dementia	17 (0.9)	5 (0.8)	22 (0.9)	0.833
Coronary disease	482 (25.4)	224 (36.1)	706 (28.1)	< 0.001
COPD	328 (17.3)	113 (18.2)	441 (17.5)	0.606
Atrial fibrillation	456 (24.1)	104 (16.8)	560 (22.3)	< 0.001
Thyroid disease	279 (14.7)	109 (17.6)	388 (15.4)	0.088
Chronic kidney disease	257 (13.6)	177 (28.5)	434 (17.3)	< 0.001
Valvular disease	342 (18.1)	87 (14.0)	429 (17.1)	0.021
Smoking habits (former or current)	341 (18)	112 (18.1)	453 (18)	0.836
CABG	109 (5.8)	61 (9.8)	170 (6.8)	< 0.001
Dyslipidemia	427 (22.5)	220 (35.5)	647 (25.7)	< 0.001
Ischaemic heart disease	475 (25.1)	218 (35.2)	693 (27.6)	< 0.001
Chagas' disease	76 (4.0)	12 (1.9)	88 (3.5)	0.015
NYHA				0.094
I	241 (12.7)	57 (9.2)	298 (11.9)	
II	998 (52.7)	352 (56.8)	1350 (53.7)	
III	565 (29.8)	182 (29.4)	747 (29.7)	
IV	90 (4.8)	29 (4.7)	119 (4.7)	
ACC/AHA classification				0.805
C	1792 (94.6)	585 (94.4)	2377 (94.6)	
D	102 (5.4)	35 (5.7)	137 (5.5)	
ACEI	674 (35.6)	172 (27.7)	846 (33.7)	< 0.001
ARB	766 (40.4)	303 (48.9)	1069 (42.5)	< 0.001
Diuretics	1257 (66.4)	436 (70.3)	1693 (67.3)	0.068
Beta-blockers	1639 (86.5)	550 (88.7)	2189 (87.1)	0.162
ARNI	176 (9.3)	69 (11.1)	245 (9.7)	0.181
MRA	1082 (57.1)	317 (51.1)	1399 (55.6)	0.009
Ivabradine	111 (5.9)	39 (6.3)	150 (5.9)	0.790
Digoxin	206 (10.9)	45 (7.3)	251 (10.0)	0.009
Nitrates	62 (3.3)	29 (4.7)	91 (3.6)	0.104
Antiagregants	804 (42.4)	356 (57.4)	1160 (46.1)	< 0.001
Statins	984 (52.0)	407 (65.6)	1391 (55.3)	< 0.001
Anticoagulants	506 (26.7)	137 (22.1)	643 (25.6)	0.022
Pacemaker				0.975
Dual-chamber	73 (3.9)	25 (4.0)	98 (3.9)	
Single-chamber	37 (2.0)	12 (1.9)	49 (2.0)	
Other implantable devices				0.826
ICD	286 (15.1)	84 (13.6)	370 (14.7)	
Resynchronization therapy	35 (1.8)	13 (2.1)	48 (1.9)	
ICD + resynchronization therapy	98 (5.2)	29 (4.7)	127 (5.1)	
Sinus rhythm	636 (33.6)	231 (37.3)	867 (34.5)	0.094
QRS complex				
< 120 ms	633 (33.4)	200 (32.3)	833 (33.1)	0.785
> 120 ms	42 (2.2)	17 (2.7)	59 (2.3)	
LV diastolic diameter	57 (48-65)	55 (48-63)	57 (48-65)	0.045
LVEF	32 (25-42)	33 (25-42)	33 (25-42)	0.645
Hemoglobin (mg/dl)	13 (12.14)	12 (11.14)	13 (12.14)	< 0.001
Anemia	494 (35.4)	232 (48.3)	726 (38.7)	< 0.001
Serum creatinine	1.1 (0.9-1.35)	1.2 (0.9-1.6)	1.1 (0.9-1.4)	< 0.001
GFR (ml/min/1.73 m ²)	59 (44.78)	53 (36.74)	57 (43.77)	< 0.001
Hyponatremia	1079 (56.9)	390 (62.9)	1469 (58.5)	< 0.001
Hyperkalemia	113 (8.3)	63 (12.6)	176 (9.4)	0.005
NT-proBNP	2151 (855-5089)	2795 (1002-6857)	2255 (950-5594)	0.101

COPD: Chronic obstructive pulmonary disease; CABG: Coronary artery bypass grafting; NYHA: New York Heart Association; ACC/AHA: American College of Cardiology/American Heart Association; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blockers; ARNI: Angiotensin receptor-neprilysin inhibitor; MRA: Mineralocorticoid receptor antagonist; ICD: Implantable cardioverter defibrillator; LV: Left ventricle; LVEF: Left ventricular ejection fraction; GFR: Glomerular filtration rate; NT-proBNP: N-terminal pro b-type natriuretic peptide

Table 2. Factors independently associated with short-term mortality in the current cohort of heart failure patients. The logistic regression model was also adjusted by age, sex, chronic kidney disease, New York Heart Association classification, and left ventricular ejection fraction.

Factor	Hazard ratio (95% CI)	P value
COPD	1.76 (1.03-3.02)	0.039
Sinus rhythm	0.56 (0.34-0.92)	0.022
Triple therapy	0.41 (0.23-0.73)	0.003
Nitrates use	3.01 (1.19-7.63)	0.020
Statins use	0.48 (0.28-0.80)	0.005
Anemia	1.85 (1.12-3.04)	0.016
Hyperkalemia	3.09 (1.64-5.83)	0.001

CI: Confidence interval; COPD: Chronic obstructive pulmonary disease

Mortality and associated factors

The median follow-up time was 215 days (Q₁: 188; Q₃: 254). A total of 170 patients (6.76%) died during the follow-up, for a mortality rate of 0.29 per 1,000 person-years (95% CI: 25.4-34.5). Significantly higher mortality was observed in the type 2 diabetes mellitus group than in the non-diabetic group (8.9% vs. 6.1%, respectively; $p = 0.016$). Supplementary table 1 summarizes the association between the evaluated variables and mortality use a bivariate analysis. From these variables, we included those that were significantly associated with mortality in the multivariable Cox regression model. Finally, after adjusting by age, sex, type 2 diabetes mellitus, chronic kidney disease, NYHA classification, and left ventricle ejection fraction, seven independent predictors of short-term mortality were identified (table 2).

Furthermore, we also analyzed the variables associated with mortality in the type 2 diabetes mellitus subgroup (table 3). In this specific sub-group, only chronic kidney disease, smoking status, statins use, anticoagulants use, left ventricle diastolic diameter, and anemia were significantly associated with the mortality outcome, being some of these factors different from those observed in the general cohort. The multivariate analysis showed that only the left ventricle diastolic diameter was an independent mortality predictor in the type 2 diabetes mellitus group (HR = 0.96; 95% CI: 0.93-0.98).

Interaction and effect modification by diabetes mellitus

There were relevant differences when assessing the independent factors by the type 2 diabetes mellitus group. At first, patients receiving triple medical therapy in the non-type 2 diabetes mellitus group had significantly lower mortality than those not receiving this therapeutic scheme.

On the other hand, the incidence of mortality was not statistically different in the group of patients with type 2 diabetes mellitus (figure 1). A similar result was observed regarding the report of sinus rhythm in the last electrocardiogram performed. No additional significant differences were observed for the other independent predictor variables.

Despite these findings, there was no evidence of effect modification by type 2 diabetes mellitus on the relationship between any of the independent predictors and all-cause mortality (figure 2). Furthermore, no interaction terms by type 2 diabetes mellitus were observed in the assessed sample (figure 2). Nevertheless, an interesting result was observed when assessing smoking history. Although it was not an independent predictor of short-term mortality in the general cohort, patients with type 2 diabetes mellitus and tobacco consumption (current or former) had a significantly higher risk of mortality (HR

= 1.84; 95% CI: 1.01-3.35) while the difference was not statistically significant in non-diabetic individuals (HR = 0.61; 95% CI: 0.35-1.11). Moreover, a significant effect modification by type 2 diabetes mellitus on the association between tobacco consumption and mortality was observed (p value = 0.005), along with a significant interaction term between both variables (p value for interaction = 0.010).

Table 3. A bivariate analysis evaluating the association between the sociodemographic and clinical variables with short-term all-cause mortality in patients with type 2 diabetes mellitus diagnosis of the *Registro Colombiano de Insuficiencia Cardíaca* (RECOLFACA)

	Alive (n = 565) n (%)	Dead (n = 55) n (%)	Total (N = 620) n (%)	p value
Sex				
Female	250 (44.25)	27 (49.09)	277 (44.68)	0.490
Male	315 (55.75)	28 (50.91)	343 (55.32)	
Age (years)	69 (62.77)	69 (63.79)	69 (62.77)	0.453
Race				
Asian	1 (0.18)	0 (0)	1 (0.16)	
White	29 (5.13)	2 (3.64)	31 (5)	
Indigenous	1 (0.18)	0 (0)	1 (0.16)	0.167
Hispanic	420 (74.34)	35 (63.64)	455 (73.39)	
Mestiza	102 (18.05)	14 (25.45)	116 (18.71)	
African-American	12 (2.12)	4 (7.27)	16 (2.58)	
Hypertension	478 (84.60)	50 (90.91)	528 (85.16)	0.209
Current alcoholism	14 (2.48)	3 (5.45)	17 (2.74)	0.197
Cancer	21 (3.72)	5 (9.09)	26 (4.19)	0.058
Coronary disease	200 (35.40)	24 (43.64)	224 (36.13)	0.225
COPD	99 (17.52)	14 (25.45)	113 (18.23)	0.146
Atrial fibrillation	92 (16.28)	12 (21.82)	104 (16.77)	0.294
Thyroid disease	96 (16.99)	13 (23.64)	109 (17.58)	0.216
Chronic kidney disease	153 (27.08)	24 (43.64)	177 (28.55)	0.009
Valvular disease	80 (14.16)	7 (12.73)	87 (14.03)	0.770
Smoking habits (former or current)	96 (16.99)	16 (29.09)	112 (18.06)	0.026
CABG	57 (10.09)	4 (7.27)	61 (9.84)	0.503
Dyslipidemia	206 (36.46)	14 (25.45)	220 (35.48)	0.103
Chagas disease	11 (1.95)	1 (1.82)	12 (1.94)	0.947
NYHA				
I	54 (9.56)	3 (5.45)	57 (9.19)	
II	325 (57.52)	27 (49.09)	352 (56.77)	0.167
III	162 (28.67)	20 (36.36)	182 (29.35)	
IV	24 (4.25)	5 (9.09)	29 (4.68)	
ACC/AHA classification				
C	533 (94.34)	52 (94.55)	585 (94.35)	0.949
D	32 (5.66)	3 (5.45)	35 (5.65)	
Triple therapy	242 (42.83)	24 (43.64)	266 (42.90)	0.908
Diuretics	391 (69.20)	45 (81.82)	436 (70.32)	0.051
Digoxin	40 (7.08)	5 (9.09)	45 (7.26)	0.583
Nitrates	24 (4.25)	5 (9.09)	29 (4.68)	0.104
Antiplatelet	328 (58.05)	28 (50.91)	356 (57.42)	0.306
Statins	380 (67.26)	27 (49.09)	407 (65.65)	0.007
Anticoagulants	117 (20.71)	20 (36.36)	137 (22.10)	0.008
Pacemaker				0.054
Dual-chamber	24 (4.25)	1 (1.81)	25 (4.42)	
Single-chamber	9 (1.59)	3 (5.45)	12 (2.12)	
Other implantable devices				0.181
ICD	94 (16.64)	12 (21.82)	106 (17.10)	
Resynchronization therapy	10 (1.77)	3 (5.45)	13 (2.10)	
ICD + resynchronization therapy	27 (4.78)	2 (3.62)	29 (4.68)	
Sinusal rhythm	213 (68.93)	18 (72)	231 (69.16)	0.749
Prolonged QRS complex	126 (40.78)	8 (32)	134 (40.12)	0.389
LV diastolic diameter	55 (48.63)	50.5 (3958)	55 (4863)	0.015
LVEF	34 (25.43)	28 (2040)	33 (2542)	0.101
Anemia	212 (48.51)	20 (46.51)	232 (48.33)	0.007
Serum creatinine	1.2 (0.93-1.60)	1.29 (1.1.8)	1.2 (0.95-1.61)	0.409
GFR (ml/min/1.73 m ³)	53.35 (36.05-75.24)	52.37 (33.05-66.58)	53.3 (35.71-74.21)	0.521
Hyponatremia	61 (14.59)	9 (21.43)	70 (15.22)	0.240
Hyperkalemia	54 (11.82)	9 (20.45)	63 (12.57)	0.099
NT-proBNP	2790 (1099-5896)	9496 (996- 1671)	2795 (1002-6857)	0.254

COPD: Chronic obstructive pulmonary disease; CABG: Coronary artery bypass grafting; NYHA: New York Heart Association; ACC/AHA: American College of Cardiology/American Heart Association; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blockers; ARNI: Angiotensin receptor-neprilysin Inhibitor; MRA: Mineralocorticoid receptor antagonist; ICD: Implantable cardioverter defibrillator; LV: Left ventricle; LVEF: Left ventricular ejection fraction; GFR: Glomerular filtration rate; NT-proBNP: N-terminal pro b-type natriuretic peptide




Figure 1. Mortality in patients according to sinus rhythm and triple therapy [angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), beta-blocker and mineralocorticoid receptor antagonist (MRA)] by type 2 diabetes mellitus group.




Figure 2. Adjusted association of each independent predictor by type 2 diabetes mellitus group and all-cause mortality. The p value for effect modification was calculated using the Mantel-Haenszel test of homogeneity.

Discussion

In the present study, the differential characteristics of patients with heart failure with and without type 2 diabetes mellitus enrolled in the RECOLFACA were described. Almost one-fourth of the patients with heart failure from the registry had a concomitant diagnosis of type 2 diabetes mellitus, highlighting a lower use of MRA, ACEI, and digoxin in these patients, along with a higher prevalence of chronic kidney disease, anemia, and electrolytic disorders. Finally, type 2 diabetes mellitus had a higher risk of mortality in the univariate analysis. Only COPD, nitrate use, anemia, and hyperkalemia were independently associated with higher mortality risk in the general cohort. In contrast, sinus rhythm, triple therapy with ACEI/ARB, MRA and beta-blockers,

and statin use were associated with a lower risk of this outcome. Regarding the type 2 diabetes mellitus group, only left ventricle diastolic diameter was independently associated with mortality.

Finally, in our registry, type 2 diabetes mellitus diagnosis did not modify the effect of independent predictors of all-cause mortality in patients with heart failure after adjusting by relevant sociodemographic and clinical variables. Likewise, several studies have evaluated the potential effect modification that type 2 diabetes mellitus could exert in different contexts, but only some of those performed in cardiovascular disease settings have reported that type 2 diabetes mellitus does not modify mortality risk when several risk factors are present (10,14,15). The study by Selvarajah *et al.* (10), which evaluated patients with cardiovascular disease, observed that type 2 diabetes mellitus diagnosis did not modify the effect of renal impairment with all-cause mortality after a follow-up of 33.198 person-years. Similarly, Gerstein *et al.* (14) observed that microalbuminuria was an independent risk factor for all-cause mortality both in patients with and without type 2 diabetes mellitus diagnosis. On the other hand, Ahmed *et al.* (15) reported that type 2 diabetes mellitus modified the effect of eGFR regarding all-cause mortality risk; however, their analysis was not adjusted by albuminuria, which precluded a more precise assessment due to the impact of albuminuria in the risk of mortality.

In regard to the higher mortality found in the type 2 diabetes mellitus group when compared to non-diabetics, our results coincide with those reported in the meta-analysis performed by Dauriz *et al.* (16), where they found approximately 30% increased risk of all-cause death. Moreover, they reported that nearly one-quarter of the patients with heart failure had diabetes, similar to what we reported in the RECOLFACA. The AMERICCAASS is a recent registry that also included heart failure patients older than 18 years, that reported a similar finding of 28% patients with heart failure and diabetes in their results from the first 1,000 patients enrolled from different Latin American countries, including Colombia (17). Another large registry that analyzed data from more than 45,000 patients from different continents, including Latin America, was the Reduction of Atherothrombosis for Continued Health (REACH) registry, where approximately 30% of increased mortality in diabetic group vs. non-diabetics was also found. However, the inclusion criteria of the REACH registry are different from ours as they not only included patients older than 18 years with heart failure, but all patients ≥ 45 years old that had established atherosclerosis or ≥ 3 risk factors for atherosclerosis, hence, the results are not comparable to ours.

In our study patients with type 2 diabetes mellitus and tobacco consumption had a significantly higher risk of mortality. A related finding was reported by the study of Jeong *et al.* (18) where they analyzed data from 349,137 type 2 diabetes mellitus Korean patients with current or history of smoking. In their study they reported that smoking cessation was associated with a 10% lower risk of all-cause mortality. However, contrary to our study, the population they studied did not have heart failure as a baseline condition, hence, our results are not completely comparable. This could suggest that the higher risk of mortality seen between patients with type 2 diabetes mellitus and tobacco consumption (current or former), has no direct relation to the heart failure diagnosis they had.

Our results regarding the variables that are independently associated with higher mortality risk in the general cohort coincide with previous reports.

Although few studies have analyzed the prognosis of patients with heart failure and COPD, it has been reported as an independent predictor of death and heart failure hospitalization when reported in multivariable models (19). Only one study has explored the causes of increased mortality (20).

According to a study with 4606 acute care patients with congestive heart failure, the use of nitrates is associated with increased relative risk of in-hospital mortality (21). Anemia has been found as an independent predictor by multiple studies, including the study by Gupta *et al.* (22) where they found that anemia emerged as an independent predictor of all-cause mortality and heart failure hospitalizations at the end of the follow-up, and the recent study by Köseoğlu *et al.* (23) who found similar results. Lastly, hyperkalemia is a known risk factor for mortality among critically ill patients and cardiac patients (24).

The systematic review of Girerd *et al.* (25) showed that the benefits of heart failure treatment appear to be similar in patients with type 2 diabetes mellitus as in non-diabetic patients, suggesting a lack of effect modification by this condition.

However, Kroon *et al.* (26) assessed the potential effect modification by type 2 diabetes mellitus in the association between B-type natriuretic peptide (BNP) and changes in left ventricular function markers in patients with incipient heart failure. In this study, type 2 diabetes mellitus modified BNP's effect over left ventricular mass index, left atrial volume * left ventricular mass index, and E/e' ratio, even after adjustment by sex, age, baseline left ventricular mass index, body mass index, and use of antihypertensives.

Finally, Ebong *et al.* (27) reported that type 2 diabetes mellitus, independently of its treatment and severity, modified the effect of the association between lipid fractions and incident heart failure, potentially due to the pathophysiological process of glucolipotoxicity. Although in our study type 2 diabetes mellitus was identified as a significant effect modifier of the impact of smoking habits and mortality, there are no previous reports on this specific topic. However, it is worth mentioning that cigarette smoking has been identified as a contributor to all-cause mortality in the general population, which is expected to be similar in type 2 diabetes mellitus patients (28). Moreover, among type 2 diabetes mellitus patients, cigarette smoking may accelerate cardiovascular disease mortality (29,30).

Regarding treatment, for several years, there were concerns about the use of beta-blockers in patients with type 2 diabetes mellitus due to the perceived risk of hypoglycemia, limiting their use in patients with heart failure and type 2 diabetes mellitus despite the benefit observed in heart failure trials (25,31). Furthermore, several clinical trials have reported that the impact of heart failure medical therapy on prospective outcomes in patients with type 2 diabetes mellitus could be significantly different from the one observed in non-diabetic patients (32). Unfortunately, some of these trials were performed in the 80s and 90s; thus, these studies did not assess interactions and effect modifications.

A recent post-hoc analysis and meta-analysis have suggested that the efficacy of the therapy with ACEI/ARB, MRA, and beta-blockers is similar in heart failure patients with and without type 2 diabetes mellitus, observations that are consistent with the results of the present study (33-36). These findings' relevance lies in the possibility of promoting an optimal medical treatment for patients with heart failure despite being diabetic or not (37). To achieve this

goal, non-cardiologists who treat patients with heart failure and type 2 diabetes mellitus should be invited to actively participate in the therapeutic optimization process and patient referral to specialized centers for interventional strategies. The involvement of nurses, general practitioners, internal medicine specialists, endocrinologists, and diabetologists in the process of up-titration of heart failure medications has been shown to be safe and efficient in achieving target doses of ACEI/ARB, MRA, and beta-blockers (36-38).

Finally, our findings showed that several comorbidities and clinical conditions were independently associated with a higher risk of short-term mortality in heart failure patients, which is consistent with the literature (39-42). The effect of these conditions on short term mortality risk was not modified by type 2 diabetes mellitus; nonetheless, we observed a significant effect modification by type 2 diabetes mellitus in the association between smoking status and mortality. This finding may derive from the common pathophysiological processes that both type 2 diabetes mellitus and smoking promote, which results in a higher incidence of macrovascular and microvascular complications due to a synergistic negative effect of these two conditions combined (43,44).

Limitations of the study

The present study had from several limitations. The RECOLFACA does not collect information regarding HbA1C levels or antidiabetic treatment; therefore, adjustment by these important variables was not possible. Moreover, no information was available on the duration and severity of type 2 diabetes mellitus, including organ involvement. In addition, only a short follow-up was available for the analyses, therefore limiting the precision of the calculated estimates. Lack of power could have been an issue in the present study, potentially leading to false non-significance when the interaction terms and effect modifications were assessed. Moreover, several potential sources of variation were not accounted for in the present study such as body mass index or other relevant diagnoses like asthma. Finally, it was not possible to have data from all patients regarding echocardiographic variables which could be a confounding factor. Therefore, our results should be interpreted with caution.

RECOLFACA is the largest multicentric registry from Colombian patients with heart failure. In this registry, patients with type 2 diabetes mellitus were less frequently treated with MRA, ACEI, and digoxin than non-diabetics while having a higher mortality rate. Moreover, several clinical conditions were independently associated with mortality in this registry. Our results also suggest that type 2 diabetes mellitus diagnosis does not modify the effect of the independent risk factors for mortality in heart failure evaluated. However, type 2 diabetes mellitus was observed to significantly modify the risk relation between mortality and smoking in patients with heart failure.

Competency in patient care and procedural skills: patients with heart failure and type 2 diabetes mellitus in Colombia are less frequently treated with important heart failure drugs compared to non-diabetics, highlighting the need of optimizing the pharmacological therapy in this population. Finally, although type 2 diabetes mellitus did not modify the effect of mortality risk factors in heart failure, it seems it can elicit a relevant effect modification in the relationship between smoking history and mortality.

Translational outlook: Further research is needed to assess the role of type 2 diabetes mellitus as an effect modifier for risk factors of all-cause mortality in heart failure patients.

Acknowledgments

List of members of the RECOLFACA Group

Alberto Cadena, Clínica de la Costa, Barranquilla, Colombia
 Alejandro D. Ochoa-Morón, Instituto Cardiovascular del Cesar - ICVC, Cesar, Colombia
 Alejandro Posada-Bastidas, Centro Cardiovascular Somer Incare, Rionegro, Colombia
 Álex Rivera-Toquica, Centro Médico para el Corazón, Clínica los Rosales, Universidad Tecnológica de Pereira, Pereira, Colombia
 Alexis Llamas, Clínica Las Américas, Medellín, Colombia
 Alfonso Muñoz-Velásquez, Institución Clínica Iberoamérica, Barranquilla, Colombia
 Álvaro H. Rodríguez-Cerón, Hospital Cardiovascular de Cundinamarca, Soacha, Colombia
 Andrés F. Buitrago, Fundación Santa Fe, Bogotá, Colombia
 Ángel A. García-Peña, Hospital Universitario San Ignacio, Bogotá, Colombia
 Argemiro R. Martínez-Carvajal, Hospital Departamental Tomás Uribe Uribe, Tuluá, Colombia
 Armando Alcalá-Hernández, Procardio Caribe S.A.S., Barranquilla, Colombia
 Balkis Rolong, Cardiología Integral, Barranquilla, Colombia
 Carlos A. Rentería-Asprilla, Cardiodiagnóstico del Chocó, Quibdó, Colombia
 Carlos A. Arias-Barrera, Clínica Universitaria Colombia Colsanitas, Bogotá, Colombia
 Carlos A. Plata-Mosquera, Dime Clínica Neuro Cardiovascular, Cali, Colombia
 Clara I. Saldarriaga-Giraldo, Clínica Cardio VID, Universidad de Antioquia, Medellín, Colombia
 Claudia Victoria Anchique, Mediagnóstica, Duitama, Colombia
 Diego H. Hoyos-Ballesteros, Centro Cardiovascular & Diabetes MASSALUD, Armenia, Colombia
 Edgar E. Castro-Osorio, SES Hospital Universitario de Caldas, Manizales, Colombia
 Eduardo J. Echeverri-Navarrete, Clínica de Occidente, Cali, Colombia
 Elkin G. Ramírez-Puentes, Sociedad Cardiológica Colombiana S.A.S., Villavicencio, Colombia
 Erika Martínez, IPS Salud Social, Barranquilla, Colombia
 Fernán Mendoza-Beltrán, Fundación Clínica Shaio, Bogotá, Colombia
 Fernando Manzur-Jatín, Centro Diagnóstico Cardiológico, Cartagena, Colombia
 Fernando Rivera-Toquica, Virrey Solís IPS, Cali, Colombia
 Gary A. Baquero-Lozano, Hospital Santa Clara, Bogotá, Colombia
 Guillermo Trout Guardiola, Grupo Salud IPS, Santa Marta, Colombia
 Gustavo Moreno-Silgado, Hospicardio, Montería, Colombia
 Hugo E. Osorio-Carmona, Clínica Medilaser Neiva, Neiva, Colombia
 Jannes Buelvas-Herazo, Cardiodiagnóstico S.A., Barranquilla, Colombia
 Jorge A. Sandoval-Luna, Cardiología Siglo XXI, Ibagué, Colombia
 José I. Mosquera-Jiménez, Unidad Cardiológica del Cauca Única S.A.S., Popayán, Colombia

José L. Accini-Mendoza, Centro Científico Asistencial IPS S.A.S., Barranquilla, Colombia
 Juan A. Cerón, Unimedic IPS, Pasto, Colombia
 Juan C. García, Hospital Universidad del Norte, Barranquilla, Colombia
 Juan C. Ortega-Madariaga, Hospital Universitario Erasmo Meoz, Cúcuta, Colombia
 Juan D. López-Ponce de León, Fundación Valle de Lili, Cali, Colombia
 Juan F. Carvajal-Estupiñán, Instituto del Corazón de Bucaramanga, Bucaramanga, Colombia
 Julián R. Lugo-Peña, Clínicos IPS, Bogotá, Colombia
 Julián Vanegas-Eljach, Clínica Avidanti, Manizales, Colombia
 Lisbeth N. Morales-Rodríguez, Clínica Medilaser, Tunja, Colombia
 Luis E. Echeverría-Correa, Fundación Cardiovascular de Colombia, Floridablanca, Colombia
 Luis M. Ávila-Barros, Clínica Riohacha, Riohacha, Colombia
 Luis Silva-Díaz-Granados, Clínica Chía, Chía, Colombia
 Luz C. Zárate-Correa, Clínica Imbanaco, Hospital Universitario del Valle, Cali, Colombia
 Marco A. De León-Espitia, Cardio Care Colombia SAS, Montería, Colombia
 Mario H. Zarama-Márquez, Clínica Nuestra Señora de Fátima, Pasto, Colombia
 Nelly Velásquez-López, Clínica Medellín, Medellín, Colombia
 Nelson A. López-Garzón, Hospital Universitario San José, Popayán, Colombia
 Nelson E. Murillo-Benítez, Angiografía de Occidente, Cali, Colombia
 Óscar A. Pacheco-Jiménez, Hospital Militar Central, Bogotá, Colombia
 Óscar S. Rincón-Peña, Unidad de Diagnóstico Cardiovascular Sveins, Duitama, Colombia
 Patricia Rodríguez-Gómez, Unidad Cardiológica de Cartagena, Cartagena, Colombia
 Rafael I. Bustamante-Urzola, Rafael Bustamante y Compañía Ltda., Leticia, Colombia
 Ricardo Gómez-Paláu, Clínica Amiga, Cali, Colombia
 Rolando Palacio, Clínica Renacer, Riohacha, Colombia
 Sebastián Campbell-Quintero, Clínica Mediláser, Florencia, Colombia
 Silfriedo Arrieta-González, Hospital Universitario de Sincelejo, Sincelejo, Colombia
 Viviana Quintero-Yepes, Clínica El Rosario, Medellín, Colombia

References

1. Tousoulis D, Oikonomou E, Siasos G, Stefanadis C. Diabetes mellitus and heart failure. *Eur Cardiol.* 2014;9:37-42. <https://doi.org/10.15420/ecr.2014.9.1.37>
2. Ciapponi A, Alcaraz A, Calderón M, Matta MG, Chaparro M, Soto N, *et al.* Burden of heart failure in Latin America: A systematic review and meta-analysis. *Rev Esp Cardiol.* 2016;69:1051-60. <https://doi.org/10.1016/j.rec.2016.04.054>
3. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, *et al.* Heart disease and stroke statistics-2020 update: A report from the American Heart Association. *Circulation.* 2020;141:e139-596. <https://doi.org/10.1161/CIR.0000000000000757>
4. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. *J Epidemiol Glob Health.* 2020;10:107-11. <https://doi.org/10.2991/jegh.k.191028.001>
5. Rosano GM, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus. *Card Fail Rev.* 2017;3:52-5. <https://doi.org/10.15420/cfr.2016.20:2>
6. Kasznicki J, Drzewoski J. Heart failure in the diabetic population – pathophysiology, diagnosis and management. *Arch Med Sci.* 2014;10:546-56. <https://doi.org/10.5114/aoms.2014.43748>

7. Qazi MU, Malik S. Diabetes and cardiovascular disease: Original insights from the Framingham Heart Study. *Glob Heart*. 2013;8:43-8. <https://doi.org/10.1016/j.gheart.2012.12.008>
8. Ziaieian B, Hernández AF, DeVore AD, Wu J, Xu H, Heidenreich PA, *et al*. Long-term outcomes for heart failure patients with and without diabetes: From the Get with the Guidelines-Heart Failure Registry. *Am Heart J*. 2019;211:1-10. <https://doi.org/10.1016/j.ahj.2019.01.006>
9. Win TT, Davis HT, Laskey WK. Mortality among patients hospitalized with heart failure and diabetes mellitus: Results from the National Inpatient Sample 2000-2010. *Circ Heart Fail*. 2016;9:e003023. <https://doi.org/10.1161/CIRCHEARTFAILURE.115.003023>
10. Selvarajah S, Uiterwaal CSPM, Haniff J, van der Graaf Y, Vissere FLJ, Bots ML, *et al*. Renal impairment and all-cause mortality in cardiovascular disease: Effect modification by type 2 diabetes mellitus. *Eur J Clin Invest*. 2013;43:198-207. <https://doi.org/10.1111/eci.12035>
11. Bauters C, Lamblin N, Mc Fadden EP, van Belle E, Millaire A, de Groote P. Influence of diabetes mellitus on heart failure risk and outcome. *Cardiovasc Diabetol*. 2003;2:1. <https://doi.org/10.1186/1475-2840-2-1>
12. Gómez-Mesa JE, Saldarriaga-Giraldo CI, Echeverría LE, Luna-Bonilla P, Grupo Investigador RECOLFACA. Registro Colombiano de Falla Cardíaca (RECOLFACA): resultados. *Rev Colomb Cardiol*. 2021;28:334-42.
13. Gómez-Mesa JE, Saldarriaga CI, Echeverría LE, Luna P, RECOLFACA research group. Colombian heart failure registry (RECOLFACA): Methodology and preliminary data. *Rev Colomb Cardiol*. 2021;28:217-30.
14. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, *et al*. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA*. 2001;286:421-6. <https://doi.org/10.1001/jama.286.4.421>
15. Ahmed S, Cannon CP, Giugliano RP, Murphy SA, Morrow DA, Antman EM, *et al*. The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. *Int J Cardiol*. 2008;131:105-12. <https://doi.org/10.1016/j.ijcard.2007.09.006>
16. Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E, *et al*. Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: A meta-analysis. *Diabetes Care*. 2017;40:1597-605. <https://doi.org/10.2337/dc17-0697>
17. Gómez-Mesa JE, Gutiérrez-Posso JM, Escalante-Forero M, Córdoba-Melo BD, Cárdenas-Marín PA, Perna ER, *et al*. American registry of ambulatory or acutely decompensated heart failure (AMERICCAASS Registry): First 1000 patients. *Clin Cardiol*. 2024;47:e24182. <https://doi.org/10.1002/clc.24182>
18. Jeong SM, Yoo JE, Park J, Jung W, Lee KN, Han K, *et al*. Smoking behavior change and risk of cardiovascular disease incidence and mortality in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol*. 2023;22:193. <https://doi.org/10.1186/s12933-023-01930-4>
19. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. *Eur J Heart Fail*. 2009;11:130-9. <https://doi.org/10.1093/eurjhf/hfn013>
20. Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP, *et al*. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: Data from the Val-HeFT heart failure trial. *J Card Fail*. 2007;13:797-804. <https://doi.org/10.1016/j.cardfail.2007.07.012>
21. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy. Clinical Quality Improvement Network Investigators. *Arch Intern Med*. 1996;156:1669-73.
22. Gupta K, Kalra R, Rajapreyar I, Joly JM, Pate M, Cribbs MG, Ather S, *et al*. Anemia, mortality, and hospitalizations in heart failure with a preserved ejection fraction (from the TOPCAT Trial). *Am J Cardiol*. 2020;125:1347-54. <https://doi.org/10.1016/j.amjcard.2020.01.046>
23. Köseoğlu FD, Özlek B. Anemia and iron deficiency predict all-cause mortality in patients with heart failure and preserved ejection fraction: 6-year follow-up study. *Diagnostics (Basel)*. 2024;14:209. <https://doi.org/10.3390/diagnostics14020209>
24. Brueske B, Sidhu MS, Schulman-Marcus J, Kashani KB, Barsness GW, Jentzer JC. Hyperkalemia is associated with increased mortality among unselected cardiac intensive

- care unit patients. *J Am Heart Assoc.* 2019;8:e011814. <https://doi.org/10.1161/JAHA.118.011814>
25. Girerd N, Zannad F, Rossignol P. Review of heart failure treatment in type 2 diabetes patients: It's at least as effective as in non-diabetic patients! *Diabetes Metab.* 2015;41:446-55. <https://doi.org/10.1016/j.diabet.2015.06.004>
 26. Kroon MH, van den Hurk K, Alsema M, Kamp O, Stehouwer CDA, Henry RMA, *et al.* Prospective associations of B-type natriuretic peptide with markers of left ventricular function in individuals with and without type 2 diabetes: An 8-year follow-up of the Hoorn Study. *Diabetes Care.* 2012;35:2510-4. <https://doi.org/10.2337/dc11-1959>
 27. Ebong IA, Goff DC, Rodríguez CJ, Chen H, Sibley CT, Bertoni AG. Association of lipids with incident heart failure among adults with and without diabetes mellitus: Multiethnic Study of Atherosclerosis. *Circ Heart Fail.* 2013;6:371-8. <https://doi.org/10.1161/CIRCHEARTFAILURE.112.000093>
 28. Cho MH, Lee K, Park SM, Chang J, Choi S, Kim K, *et al.* Effects of smoking habit change on all-cause mortality and cardiovascular diseases among patients with newly diagnosed diabetes in Korea. *Sci Rep.* 2018;8:5316. <https://doi.org/10.1038/s41598-018-23729-0>
 29. Suárez L, Barrett-Connor E. Interaction between cigarette smoking and diabetes mellitus in the prediction of death attributed to cardiovascular disease. *Am J Epidemiol.* 1984;120:670-5. <https://doi.org/10.1093/oxfordjournals.aje.a113933>
 30. Gambaro G, Bax G, Fusaro M, Normanno M, Manani SM, Zanella M, *et al.* Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. *Diabetes Nutr Metab.* 2001;14:337-42.
 31. Chen J, Marciniak TA, Radford MJ, Wang Y, Krumholz HM. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients: Results from the national cooperative cardiovascular project. *J Am Coll Cardiol.* 1999;34:1388-94. [https://doi.org/10.1016/s0735-1097\(99\)00383-6](https://doi.org/10.1016/s0735-1097(99)00383-6)
 32. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. *Am Heart J.* 2003;146:848-53. [https://doi.org/10.1016/S0002-8703\(03\)00403-4](https://doi.org/10.1016/S0002-8703(03)00403-4)
 33. Shekelle PG, Rich MW, Morton SC, Atkinson ColSW, Tu W, Maglione M, *et al.* Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. *J Am Coll Cardiol.* 2003;41:1529-38. [https://doi.org/10.1016/s0735-1097\(03\)00262-6](https://doi.org/10.1016/s0735-1097(03)00262-6)
 34. MacDonald MR, Petrie MC, Varyani F, Östergren J, Michelson EL, Young JB, *et al.* Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. *Eur Heart J.* 2008;29:1377-85. <https://doi.org/10.1093/eurheartj/ehn153>
 35. Erland E, Philippe L, Patricia V, Hermann W. Results from post-hoc analyses of the CIBIS II trial: Effect of bisoprolol in high-risk patient groups with chronic heart failure. *Eur J Heart Fail.* 2001;3:469-79. [https://doi.org/10.1016/S1388-9842\(01\)00174-X](https://doi.org/10.1016/S1388-9842(01)00174-X)
 36. Rickli H, Steiner S, Müller K, Hess OM. Betablockers in heart failure: Carvedilol Safety Assessment (CASA 2-trial). *Eur J Heart Fail.* 2004;6:761-8. <https://doi.org/10.1016/j.ejheart.2003.11.025>
 37. Doughty RN, Wright SP, Pearl A, Walsh HJ, Muncaster S, Whalley GA, *et al.* Randomized, controlled trial of integrated heart failure management. The Auckland Heart Failure Management Study. *Eur Heart J.* 2002;23:139-46. <https://doi.org/10.1053/ehj.2001.2712>
 38. Driscoll A, Srivastava P, Toia D, Gibcus J, Hare DL. A nurse-led up-titration clinic improves chronic heart failure optimization of beta-adrenergic receptor blocking therapy--a randomized controlled trial. *BMC Res Notes.* 2014;7:668. <https://doi.org/10.1186/1756-0500-7-668>
 39. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJV. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. *Eur J Heart Fail.* 2009;11:130-9. <https://doi.org/10.1093/eurjhf/hfn013>

40. De Blois J, Simard S, Atar D, Agewall S, Norwegian Heart Failure Registry. COPD predicts mortality in HF: The Norwegian Heart Failure Registry. *J Card Fail.* 2010;16:225-9. <https://doi.org/10.1016/j.cardfail.2009.12.002>
41. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, *et al.* Anemia and mortality in heart failure patients a systematic review and meta-analysis. *J Am Coll Cardiol.* 2008;52:818-27. <https://doi.org/10.1016/j.jacc.2008.04.061>
42. Chairat K, Rattanaivanon W, Tanyasaenook K, Chindavijak B, Chulavatnatol S, Nathisuwan S. Relationship of anemia and clinical outcome in heart failure patients with preserved versus reduced ejection fraction in a rural area of Thailand. *Int J Cardiol Heart Vasc.* 2020;30:100597. <https://doi.org/10.1016/j.ijcha.2020.100597>
43. Pan A, Wang Y, Talaei M, Hu FB. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: A meta-analysis and systematic review. *Circulation.* 2015;132:1795-804. <https://doi.org/10.1161/CIRCULATIONAHA.115.017926>
44. Campagna D, Alamo A, Di Pino A, Russo C, Calogero AE, Purrello F, *et al.* Smoking and diabetes: dangerous liaisons and confusing relationships. *Diabetol Metab Syndr.* 2019;11:85. <https://doi.org/10.1186/s13098-019-0482-2>